Published in Rev Urol on January 01, 2000
Urinary incontinence in the elderly and age-dependent apoptosis of rhabdosphincter cells. Lancet (1999) 1.92
Laparoscopic bladder neck suspension fails the test of time. J Urol (1999) 1.09
Noninvasive urodynamic evaluation of bladder outlet obstruction using Doppler ultrasonography. Urology (2000) 1.54
Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol (2001) 1.54
1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2008) 1.45
Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. J Urol (1999) 1.41
The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2003) 1.32
Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol (1999) 1.32
Bladder and sphincter behavior in patients with spinal cord lesions. J Urol (1991) 1.28
Urodynamics of spinal cord injury. Urol Clin North Am (1996) 1.25
The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol (2001) 1.19
Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol (2001) 1.18
Neural control of the urethra. Scand J Urol Nephrol Suppl (2001) 1.17
Development of noninvasive velocity flow video urodynamics using Doppler sonography. Part II: clinical application in bladder outlet obstruction. J Urol (1998) 1.16
The involvement of the tetrodotoxin-resistant sodium channel Na(v)1.8 (PN3/SNS) in a rat model of visceral pain. J Neurosci (2001) 1.11
Development of noninvasive velocity flow video urodynamics using Doppler sonography. Part I: Experimental urethra. J Urol (1998) 1.11
Early predictors of bladder recovery and urodynamics after spinal cord injury. Neurourol Urodyn (1998) 1.09
Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor-sphincter dyssynergia application. J Urol (2000) 1.06
Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol (2000) 1.05
Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction. Gene Ther (2002) 1.04
Analysis of the afferent limb of the vesicovascular reflex using neurotoxins, resiniferatoxin and capsaicin. Am J Physiol Regul Integr Comp Physiol (2001) 1.02
Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol (2001) 1.01
Changes in micturition after spinal cord injury in conscious rats. Urology (1999) 1.00
Molecular marker for development of interstitial cystitis in rat model: isoactin gene expression. J Urol (1997) 0.98
Myoblast therapy for stress urinary incontinence and bladder dysfunction. World J Urol (2000) 0.97
Modified Burch colposuspension for stress urinary incontinence in females. Surg Gynecol Obstet (1993) 0.95
Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int (2003) 0.95
Effects of cigarette smoke components on in vitro chemotaxis of human polymorphonuclear leukocytes. Infect Immun (1977) 0.94
Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol (2001) 0.93
Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE). Urology (2001) 0.93
Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord (2000) 0.93
Influence of glutamate receptor antagonists on micturition in rats with spinal cord injury. Exp Neurol (1999) 0.92
The effect of urinary tract reconstruction on neurologically impaired women previously treated with an indwelling urethral catheter. J Urol (1996) 0.92
Persistence and survival of autologous muscle derived cells versus bovine collagen as potential treatment of stress urinary incontinence. J Urol (2001) 0.91
Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther (2009) 0.91
Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. Tech Urol (2001) 0.91
Injection of skeletal muscle-derived cells into the penis improves erectile function. Int J Impot Res (2005) 0.91
Muscle-derived cell transplantation and differentiation into lower urinary tract smooth muscle. Urology (2001) 0.90
Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther (2008) 0.89
Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Ther (2007) 0.89
Lyme cystitis and neurogenic bladder dysfunction. Lancet (1992) 0.86
High incidence of occult neurogenic bladder dysfunction in neurologically intact patients with thoracolumbar spinal injuries. J Urol (1998) 0.86
Reliability of color Doppler ultrasound urodynamics in the evaluation of bladder outlet obstruction. Urology (2000) 0.86
Autologous primary muscle-derived cells transfer into the lower urinary tract. Tissue Eng (2001) 0.85
Spinal cord injury and bladder recovery. Arch Phys Med Rehabil (1996) 0.85
Pharmacologic and potential biologic interventions to restore bladder function after spinal cord injury. Curr Opin Neurol (2000) 0.85
Complications of Teflon injection for stress urinary incontinence. Neurourol Urodyn (1993) 0.83
31-Year-old bladder diverticulocutaneous fistula with a giant stone as a complication of pelvic fracture. Tech Urol (2001) 0.83
Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. Arch Phys Med Rehabil (1995) 0.83
Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up. Tech Urol (1999) 0.83
Latex allergy manifested in urological surgery and care of adult spinal cord injured patients. Arch Phys Med Rehabil (1994) 0.82
Advantages and risks of ileovesicostomy for the management of neuropathic bladder. Urology (1999) 0.82
The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group. Urology (1994) 0.82
A reliable, nondestructive animal model for interstitial cystitis: intravesical low-dose protamine sulfate combined with physiological concentrations of potassium chloride. Urology (2001) 0.82
Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct (2002) 0.81
Erectile response to topical, intraurethral and intracorporal pharmacotherapy in a rat model of spinal cord injury. J Spinal Cord Med (1995) 0.81
Intravesical neuromodulatory drugs: capsaicin and resiniferatoxin to treat the overactive bladder. J Endourol (2000) 0.81
Urodynamic monitoring during percutaneous sacral nerve neurostimulation in patients with neurogenic detrusor hyperreflexia. Neurourol Urodyn (2001) 0.80
Stem cell therapy for urethral sphincter regeneration. Minerva Urol Nefrol (2008) 0.80
Nitric oxide synthase gene therapy for erectile dysfunction: comparison of plasmid, adenovirus, and adenovirus-transduced myoblast vectors. Mol Urol (2001) 0.80
Cutaneous ileocystostomy (a bladder chimney) for the treatment of severe neurogenic vesical dysfunction. Paraplegia (1995) 0.80
Neurological manifestations of baclofen withdrawal. J Urol (1993) 0.79
Autonomic dysreflexia in a rat model spinal cord injury and the effect of pharmacologic agents. Neurourol Urodyn (1995) 0.79
Mapping the future for incontinence treatment worldwide: highlights from the first international consultation on incontinence june 28-july 1, 1998, monaco. Rev Urol (1999) 0.79
Urolume stent placement for the treatment of postbrachytherapy bladder outlet obstruction. Urology (2000) 0.79
Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene Ther (2009) 0.78
Variations in the gingival polymorphonuclear leukocyte migration rate in dogs induced by chemotactic autologous serum and migration inhibitor from tobacco smoke. J Periodontal Res (1977) 0.78
Liposomal inhibition of acrolein-induced injury in rat cultured urothelial cells. Int Urol Nephrol (2014) 0.78
Flexible cystoscopy in spinal cord injury. Review article. Paraplegia (1994) 0.78
Epidemiology of current treatment for sexual dysfunction in spinal cord injured men in the USA model spinal cord injury centers. J Spinal Cord Med (1996) 0.78
Detrusor-myoplasty to restore micturition. Lancet (1994) 0.78
Effect of intravesical capsaicin and vehicle on bladder integrity control and spinal cord injured rats. J Urol (1998) 0.77
Suppression of the tetrodotoxin-resistant sodium channel (PN3/SNS): a possible new treatment for bladder pain. Urology (2001) 0.77
Medical and minimally invasive treatment of urinary incontinence. Rev Urol (1999) 0.77
Evaluation of autologous fat implantation in the rat urinary bladder submucosa. Urology (1998) 0.77
[Pittsburgh experience with botulinum toxin A injection]. Actas Urol Esp (2006) 0.77
Gracilis muscle dynamic urethral sphincter myoplasty: rat model experience. J Urol (1996) 0.77
Intravesical capsaicin in neurologic impaired patients with detrusor hyperreflexia. J Spinal Cord Med (1996) 0.76
Neurogenic vesical dysfunction. Urol Clin North Am (1995) 0.76
Bladder autoaugmentation. Tech Urol (1995) 0.76
Malignant priapism as the initial clinical manifestation of metastatic renal cell carcinoma with invasion of both corpora cavernosum and spongiosum. Int J Impot Res (1998) 0.76
Neurovesical dysfunction in postural tachycardia syndrome (POTS). Int Urogynecol J Pelvic Floor Dysfunct (2002) 0.76
Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia (1994) 0.76
Future trends in the treatment of urinary incontinence. Rev Urol (2001) 0.76
Botulinum-A toxin: an exciting new treatment option for prostatic disease. Int J Clin Pract Suppl (2006) 0.76
Urologic manifestation of spinal cord sarcoidosis. J Spinal Cord Med (1996) 0.76
Prospective comparison of external sphincter prosthesis placement and external sphincterotomy in men with spinal cord injury. J Endourol (1994) 0.76
First-line therapy for stress incontinence. Rev Urol (2000) 0.75
Comparison of Incontinence Risk after Radical Prostatectomy versus Hysterectomy. Rev Urol (2001) 0.75
Complications associated with the use of vacuum constriction devices for erectile dysfunction in the spinal cord injured population. J Am Paraplegia Soc (1994) 0.75
What is the best way to treat incontinence: behavioral or drug treatment? Rev Urol (2000) 0.75
Managing stress incontinence and classifying detrusor instability. Rev Urol (1999) 0.75
Is nighttime voiding normal or anomalous? Rev Urol (2001) 0.75
Should we be using chili pepper extracts to treat the overactive bladder? J Urol (1997) 0.75
Should I do a pubovaginal sling operation on an obese woman? Rev Urol (2000) 0.75
Managing incontinence: the tip of the iceberg. Rev Urol (1999) 0.75
In-vivo whole bladder response to anticholinergic and musculotropic agents in spinal cord injured rats. J Spinal Cord Med (1997) 0.75
Intravesical ultrapotent vanilloid receptor agonists: acute effects on animal models of bladder irritation. Urology (2001) 0.75
Transverse retubularized ileovesicostomy continent urinary diversion to the umbilicus. Tech Urol (2000) 0.75
Spermatogenesis in early and chronic phases of experimental spinal cord injury in the rodent model. J Androl (1999) 0.75